|
|
Post by wsulylecoug on Mar 10, 2021 10:58:15 GMT -5
Mike referenced the Denver facility twice in his presentation. This is the first time I have become aware we had a Denver facility? Maybe I need to pay more attention to the company? Within the translation from voice to words, guessing the computers doing the job “heard” Danbury and interpreted as Denver. |
|
|
|
Post by liane on Mar 10, 2021 12:40:43 GMT -5
That makes sense - I've never heard of Denver facility.
|
|
|
|
Post by mango on Mar 10, 2021 13:01:02 GMT -5
Updated list of company developments.
🥭 Tyvaso DPI FDA approval this year
🥭 Afrezza Pediatrics Phase 3 clinical trial this year
🥭 Clofazimine Phase 1 this year
🥭 Royalties from Thyquidity Co-Promote w/ Vertice Pharma starts NOW
🥭 BluHale Pro Launch
🥭 Afrezza European Union filing this year
🥭 Afrezza Australia approval this year
🥭 Afrezza clinical trial for gestational diabetes incoming
🥭 Potentially over $100M in annual royalties from partner $UTHR
🥭 We have $367M in cash—enough to get us to cash flow break even—HUGE!!!
🥭 Cannabis partner Receptor Life Sciences Phase 1 incoming
🥭 Pipeline advancement
🥭 New partnerships
🥭 Afrezza India Clinical Trial starts this year
🥭 Further Debt Reduction
🥭 New Afrezza scientific publications this year
🥭 A second UT molecule incoming (post-NDA or post-FDA approval this year?)
|
|
|
|
Post by spikespiegel on Mar 10, 2021 14:00:46 GMT -5
the India Trial allready started, der was a referenz to the india trial on BP, but didnt find it.
|
|
